Compare Stocks

5 / 10
Try these comparisons:

Stock Comparison

RMD vs PHG vs SYK vs BSX vs MDT

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
RMD
ResMed Inc.

Medical - Instruments & Supplies

HealthcareNYSE • US
Market Cap$30.15B
5Y Perf.+28.7%
PHG
Koninklijke Philips N.V.

Medical - Devices

HealthcareNYSE • NL
Market Cap$25.84B
5Y Perf.-34.1%
SYK
Stryker Corporation

Medical - Devices

HealthcareNYSE • US
Market Cap$112.69B
5Y Perf.+50.3%
BSX
Boston Scientific Corporation

Medical - Devices

HealthcareNYSE • US
Market Cap$84.08B
5Y Perf.+48.9%
MDT
Medtronic plc

Medical - Devices

HealthcareNYSE • IE
Market Cap$99.94B
5Y Perf.-20.9%

RMD vs PHG vs SYK vs BSX vs MDT — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
RMD logoRMD
PHG logoPHG
SYK logoSYK
BSX logoBSX
MDT logoMDT
IndustryMedical - Instruments & SuppliesMedical - DevicesMedical - DevicesMedical - DevicesMedical - Devices
Market Cap$30.15B$25.84B$112.69B$84.08B$99.94B
Revenue (TTM)$5.54B$17.83B$25.12B$20.07B$35.48B
Net Income (TTM)$1.52B$895M$3.25B$2.89B$4.61B
Gross Margin61.7%45.2%63.5%69.0%61.9%
Operating Margin34.3%8.0%22.4%19.8%17.9%
Forward P/E18.8x17.5x19.6x16.7x14.1x
Total Debt$852M$8.09B$14.86B$12.42B$28.52B
Cash & Equiv.$1.21B$2.79B$4.01B$2.04B$2.22B

RMD vs PHG vs SYK vs BSX vs MDTLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

RMD
PHG
SYK
BSX
MDT
StockMay 20May 26Return
ResMed Inc. (RMD)100128.7+28.7%
Koninklijke Philips… (PHG)10065.9-34.1%
Stryker Corporation (SYK)100150.3+50.3%
Boston Scientific C… (BSX)100148.9+48.9%
Medtronic plc (MDT)10079.1-20.9%

Price return only. Dividends and distributions are not included.

Quick Verdict: RMD vs PHG vs SYK vs BSX vs MDT

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: RMD and BSX are tied at the top with 2 categories each (5-stock set) — the right choice depends on your priorities. Boston Scientific Corporation is the stronger pick specifically for growth and revenue expansion and capital preservation and lower volatility. MDT and PHG also each lead in at least one category. As sector peers, any of these can serve as alternatives in the same allocation.
RMD
ResMed Inc.
The Long-Run Compounder

RMD has the current edge in this matchup, primarily because of its strength in long-term compounding and valuation efficiency.

  • 293.8% 10Y total return vs SYK's 187.1%
  • PEG 1.08 vs MDT's 36.00
  • Better valuation composite
  • 27.4% margin vs PHG's 5.0%
Best for: long-term compounding and valuation efficiency
PHG
Koninklijke Philips N.V.
The Momentum Pick

PHG is the clearest fit if your priority is momentum.

  • +17.7% vs BSX's -46.0%
Best for: momentum
SYK
Stryker Corporation
The Lower-Volatility Pick

Among these 5 stocks, SYK doesn't own a clear edge in any measured category.

Best for: healthcare exposure
BSX
Boston Scientific Corporation
The Growth Play

BSX is the #2 pick in this set and the best alternative if growth exposure and sleep-well-at-night is your priority.

  • Rev growth 19.9%, EPS growth 55.2%, 3Y rev CAGR 16.5%
  • Lower volatility, beta 0.34, Low D/E 50.7%, current ratio 1.62x
  • 19.9% revenue growth vs PHG's -1.0%
  • Beta 0.34 vs PHG's 1.12, lower leverage
Best for: growth exposure and sleep-well-at-night
MDT
Medtronic plc
The Income Pick

MDT ranks third and is worth considering specifically for income & stability and defensive.

  • Dividend streak 36 yrs, beta 0.47, yield 3.6%
  • Beta 0.47, yield 3.6%, current ratio 1.85x
  • 3.6% yield, 36-year raise streak, vs PHG's 1.5%, (1 stock pays no dividend)
  • 175.8% ROA vs PHG's 3.4%, ROIC 6.0% vs 6.4%
Best for: income & stability and defensive
See the full category breakdown
CategoryWinnerWhy
GrowthBSX logoBSX19.9% revenue growth vs PHG's -1.0%
ValueRMD logoRMDBetter valuation composite
Quality / MarginsRMD logoRMD27.4% margin vs PHG's 5.0%
Stability / SafetyBSX logoBSXBeta 0.34 vs PHG's 1.12, lower leverage
DividendsMDT logoMDT3.6% yield, 36-year raise streak, vs PHG's 1.5%, (1 stock pays no dividend)
Momentum (1Y)PHG logoPHG+17.7% vs BSX's -46.0%
Efficiency (ROA)MDT logoMDT175.8% ROA vs PHG's 3.4%, ROIC 6.0% vs 6.4%

RMD vs PHG vs SYK vs BSX vs MDT — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

RMDResMed Inc.
FY 2024
Sleep And Respiratory
87.5%$4.1B
Software As Service
12.5%$584M
PHGKoninklijke Philips N.V.

Segment breakdown not available.

SYKStryker Corporation
FY 2025
MedSurg
62.3%$15.6B
Orthopaedics
37.7%$9.5B
BSXBoston Scientific Corporation
FY 2025
Cardiovascular
66.0%$13.3B
MedSurg
34.0%$6.8B
MDTMedtronic plc
FY 2025
Cardiac and Vascular Group
37.3%$12.5B
Neuroscience Group
29.4%$9.8B
Medical Surgical
25.1%$8.4B
Diabetes Group
8.2%$2.8B

RMD vs PHG vs SYK vs BSX vs MDT — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLRMDLAGGINGBSX

Income & Cash Flow (Last 12 Months)

RMD leads this category, winning 3 of 6 comparable metrics.

MDT is the larger business by revenue, generating $35.5B annually — 6.4x RMD's $5.5B. RMD is the more profitable business, keeping 27.4% of every revenue dollar as net income compared to PHG's 5.0%. On growth, BSX holds the edge at +15.9% YoY revenue growth, suggesting stronger near-term business momentum.

MetricRMD logoRMDResMed Inc.PHG logoPHGKoninklijke Phili…SYK logoSYKStryker Corporati…BSX logoBSXBoston Scientific…MDT logoMDTMedtronic plc
RevenueTrailing 12 months$5.5B$17.8B$25.1B$20.1B$35.5B
EBITDAEarnings before interest/tax$2.1B$2.5B$6.3B$4.7B$9.4B
Net IncomeAfter-tax profit$1.5B$895M$3.2B$2.9B$4.6B
Free Cash FlowCash after capex$1.8B$755M$4.3B$3.6B$5.4B
Gross MarginGross profit ÷ Revenue+61.7%+45.2%+63.5%+69.0%+61.9%
Operating MarginEBIT ÷ Revenue+34.3%+8.0%+22.4%+19.8%+17.9%
Net MarginNet income ÷ Revenue+27.4%+5.0%+12.9%+14.4%+13.0%
FCF MarginFCF ÷ Revenue+31.7%+4.2%+17.1%+18.1%+15.2%
Rev. Growth (YoY)Latest quarter vs prior year+10.8%+1.1%+11.4%+15.9%+8.8%
EPS Growth (YoY)Latest quarter vs prior year+9.3%+2.1%+56.0%+18.5%-11.9%
RMD leads this category, winning 3 of 6 comparable metrics.

Valuation Metrics

PHG leads this category, winning 3 of 7 comparable metrics.

At 21.6x trailing earnings, MDT trades at a 38% valuation discount to SYK's 35.0x P/E. Adjusting for growth (PEG ratio), RMD offers better value at 1.25x vs MDT's 36.00x — a lower PEG means you pay less per unit of expected earnings growth.

MetricRMD logoRMDResMed Inc.PHG logoPHGKoninklijke Phili…SYK logoSYKStryker Corporati…BSX logoBSXBoston Scientific…MDT logoMDTMedtronic plc
Market CapShares × price$30.1B$25.8B$112.7B$84.1B$99.9B
Enterprise ValueMkt cap + debt − cash$29.8B$32.1B$123.5B$94.5B$126.2B
Trailing P/EPrice ÷ TTM EPS21.76x24.85x35.03x29.16x21.60x
Forward P/EPrice ÷ next-FY EPS est.18.78x17.55x19.62x16.75x14.13x
PEG RatioP/E ÷ EPS growth rate1.25x2.36x36.00x
EV / EBITDAEnterprise value multiple15.51x10.70x20.31x25.30x14.32x
Price / SalesMarket cap ÷ Revenue5.86x1.23x4.49x4.19x2.98x
Price / BookPrice ÷ Book value/share5.11x2.02x5.02x3.46x2.08x
Price / FCFMarket cap ÷ FCF18.14x24.62x26.31x22.99x19.28x
PHG leads this category, winning 3 of 7 comparable metrics.

Profitability & Efficiency

RMD leads this category, winning 8 of 9 comparable metrics.

RMD delivers a 24.4% return on equity — every $100 of shareholder capital generates $24 in annual profit, vs $8 for PHG. RMD carries lower financial leverage with a 0.14x debt-to-equity ratio, signaling a more conservative balance sheet compared to PHG's 0.74x. On the Piotroski fundamental quality scale (0–9), RMD scores 8/9 vs MDT's 6/9, reflecting strong financial health.

MetricRMD logoRMDResMed Inc.PHG logoPHGKoninklijke Phili…SYK logoSYKStryker Corporati…BSX logoBSXBoston Scientific…MDT logoMDTMedtronic plc
ROE (TTM)Return on equity+24.4%+8.2%+15.0%+12.4%+9.4%
ROA (TTM)Return on assets+18.0%+3.4%+6.9%+6.9%+175.8%
ROICReturn on invested capital+22.8%+6.4%+11.4%+8.8%+6.0%
ROCEReturn on capital employed+25.7%+7.1%+13.0%+11.1%+7.5%
Piotroski ScoreFundamental quality 0–987676
Debt / EquityFinancial leverage0.14x0.74x0.66x0.51x0.59x
Net DebtTotal debt minus cash-$358M$5.3B$10.8B$10.4B$26.3B
Cash & Equiv.Liquid assets$1.2B$2.8B$4.0B$2.0B$2.2B
Total DebtShort + long-term debt$852M$8.1B$14.9B$12.4B$28.5B
Interest CoverageEBIT ÷ Interest expense66.06x4.34x6.72x11.03x9.08x
RMD leads this category, winning 8 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

PHG leads this category, winning 4 of 6 comparable metrics.

A $10,000 investment in BSX five years ago would be worth $13,117 today (with dividends reinvested), compared to $5,734 for PHG. Over the past 12 months, PHG leads with a +17.7% total return vs BSX's -46.0%. The 3-year compound annual growth rate (CAGR) favors PHG at 11.6% vs RMD's -2.9% — a key indicator of consistent wealth creation.

MetricRMD logoRMDResMed Inc.PHG logoPHGKoninklijke Phili…SYK logoSYKStryker Corporati…BSX logoBSXBoston Scientific…MDT logoMDTMedtronic plc
YTD ReturnYear-to-date-15.2%+0.3%-15.2%-40.3%-18.1%
1-Year ReturnPast 12 months-14.5%+17.7%-22.5%-46.0%-2.8%
3-Year ReturnCumulative with dividends-8.4%+38.8%+5.5%+6.5%-4.2%
5-Year ReturnCumulative with dividends+11.0%-42.7%+21.5%+31.2%-27.7%
10-Year ReturnCumulative with dividends+293.8%+48.3%+187.1%+155.5%+26.5%
CAGR (3Y)Annualised 3-year return-2.9%+11.6%+1.8%+2.1%-1.4%
PHG leads this category, winning 4 of 6 comparable metrics.

Risk & Volatility

Evenly matched — PHG and BSX each lead in 1 of 2 comparable metrics.

BSX is the less volatile stock with a 0.34 beta — it tends to amplify market swings less than PHG's 1.12 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. PHG currently trades 81.2% from its 52-week high vs BSX's 51.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricRMD logoRMDResMed Inc.PHG logoPHGKoninklijke Phili…SYK logoSYKStryker Corporati…BSX logoBSXBoston Scientific…MDT logoMDTMedtronic plc
Beta (5Y)Sensitivity to S&P 5000.66x1.12x0.55x0.34x0.47x
52-Week HighHighest price in past year$293.81$33.44$404.87$109.50$106.33
52-Week LowLowest price in past year$198.64$21.95$289.91$54.98$77.16
% of 52W HighCurrent price vs 52-week peak+70.4%+81.2%+72.7%+51.7%+73.3%
RSI (14)Momentum oscillator 0–10035.647.724.333.227.3
Avg Volume (50D)Average daily shares traded1.1M1.0M2.1M15.5M7.8M
Evenly matched — PHG and BSX each lead in 1 of 2 comparable metrics.

Analyst Outlook

MDT leads this category, winning 2 of 2 comparable metrics.

Analyst consensus: RMD as "Buy", PHG as "Hold", SYK as "Buy", BSX as "Buy", MDT as "Buy". Consensus price targets imply 61.4% upside for BSX (target: $91) vs 35.9% for RMD (target: $281). For income investors, MDT offers the higher dividend yield at 3.57% vs RMD's 1.02%.

MetricRMD logoRMDResMed Inc.PHG logoPHGKoninklijke Phili…SYK logoSYKStryker Corporati…BSX logoBSXBoston Scientific…MDT logoMDTMedtronic plc
Analyst RatingConsensus buy/hold/sellBuyHoldBuyBuyBuy
Price TargetConsensus 12-month target$281.29$403.69$91.33$109.50
# AnalystsCovering analysts3522504349
Dividend YieldAnnual dividend ÷ price+1.0%+1.5%+1.1%+3.6%
Dividend StreakConsecutive years of raises14134036
Dividend / ShareAnnual DPS$2.11$0.34$3.36$2.78
Buyback YieldShare repurchases ÷ mkt cap+1.0%0.0%0.0%0.0%+3.2%
MDT leads this category, winning 2 of 2 comparable metrics.
Key Takeaway

RMD leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). PHG leads in 2 (Valuation Metrics, Total Returns). 1 tied.

Best OverallResMed Inc. (RMD)Leads 2 of 6 categories
Loading custom metrics...

RMD vs PHG vs SYK vs BSX vs MDT: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is RMD or PHG or SYK or BSX or MDT a better buy right now?

For growth investors, Boston Scientific Corporation (BSX) is the stronger pick with 19.

9% revenue growth year-over-year, versus -1. 0% for Koninklijke Philips N. V. (PHG). Medtronic plc (MDT) offers the better valuation at 21. 6x trailing P/E (14. 1x forward), making it the more compelling value choice. Analysts rate ResMed Inc. (RMD) a "Buy" — based on 35 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — RMD or PHG or SYK or BSX or MDT?

On trailing P/E, Medtronic plc (MDT) is the cheapest at 21.

6x versus Stryker Corporation at 35. 0x. On forward P/E, Medtronic plc is actually cheaper at 14. 1x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: ResMed Inc. wins at 1. 08x versus Medtronic plc's 36. 00x — a reasonable growth-adjusted valuation.

03

Which is the better long-term investment — RMD or PHG or SYK or BSX or MDT?

Over the past 5 years, Boston Scientific Corporation (BSX) delivered a total return of +31.

2%, compared to -42. 7% for Koninklijke Philips N. V. (PHG). Over 10 years, the gap is even starker: RMD returned +293. 8% versus MDT's +26. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — RMD or PHG or SYK or BSX or MDT?

By beta (market sensitivity over 5 years), Boston Scientific Corporation (BSX) is the lower-risk stock at 0.

34β versus Koninklijke Philips N. V. 's 1. 12β — meaning PHG is approximately 225% more volatile than BSX relative to the S&P 500. On balance sheet safety, ResMed Inc. (RMD) carries a lower debt/equity ratio of 14% versus 74% for Koninklijke Philips N. V. — giving it more financial flexibility in a downturn.

05

Which is growing faster — RMD or PHG or SYK or BSX or MDT?

By revenue growth (latest reported year), Boston Scientific Corporation (BSX) is pulling ahead at 19.

9% versus -1. 0% for Koninklijke Philips N. V. (PHG). On earnings-per-share growth, the picture is similar: Koninklijke Philips N. V. grew EPS 224. 0% year-over-year, compared to 8. 2% for Stryker Corporation. Over a 3-year CAGR, BSX leads at 16. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — RMD or PHG or SYK or BSX or MDT?

ResMed Inc.

(RMD) is the more profitable company, earning 27. 2% net margin versus 5. 0% for Koninklijke Philips N. V. — meaning it keeps 27. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RMD leads at 32. 7% versus 8. 0% for PHG. At the gross margin level — before operating expenses — BSX leads at 69. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is RMD or PHG or SYK or BSX or MDT more undervalued right now?

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, ResMed Inc. (RMD) is the more undervalued stock at a PEG of 1. 08x versus Medtronic plc's 36. 00x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, Medtronic plc (MDT) trades at 14. 1x forward P/E versus 19. 6x for Stryker Corporation — 5. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for BSX: 61. 4% to $91. 33.

08

Which pays a better dividend — RMD or PHG or SYK or BSX or MDT?

In this comparison, MDT (3.

6% yield), PHG (1. 5% yield), SYK (1. 1% yield), RMD (1. 0% yield) pay a dividend. BSX does not pay a meaningful dividend and should not be held primarily for income.

09

Is RMD or PHG or SYK or BSX or MDT better for a retirement portfolio?

For long-horizon retirement investors, Stryker Corporation (SYK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

55), 1. 1% yield, +187. 1% 10Y return). Both have compounded well over 10 years (SYK: +187. 1%, PHG: +48. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between RMD and PHG and SYK and BSX and MDT?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: RMD is a mid-cap quality compounder stock; PHG is a mid-cap quality compounder stock; SYK is a mid-cap quality compounder stock; BSX is a mid-cap high-growth stock; MDT is a mid-cap income-oriented stock. RMD, PHG, SYK, MDT pay a dividend while BSX does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

RMD

Quality Mega-Cap Compounder

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 16%
Run This Screen
Stocks Like

PHG

Stable Dividend Mega-Cap

  • Sector: Healthcare
  • Market Cap > $100B
  • Net Margin > 5%
  • Dividend Yield > 0.5%
Run This Screen
Stocks Like

SYK

Stable Dividend Mega-Cap

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 7%
Run This Screen
Stocks Like

BSX

High-Growth Compounder

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 7%
  • Net Margin > 8%
Run This Screen
Stocks Like

MDT

Income & Dividend Stock

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 7%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform RMD and PHG and SYK and BSX and MDT on the metrics below

Revenue Growth>
%
(RMD: 10.8% · PHG: 1.1%)
Net Margin>
%
(RMD: 27.4% · PHG: 5.0%)
P/E Ratio<
x
(RMD: 21.8x · PHG: 24.9x)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.